Epsilon Molecular Engineering

What Epsilon Molecular Engineering does

Epsilon Molecular Engineering (EME) is a Japanese contract research organization and biotechnology company founded in 2016 as a spin-off from Saitama University, headquartered in Saitama City. The company builds and operates an integrated VHH (single-domain antibody) discovery platform anchored on two proprietary assets: a cDNA display technology that uses a proprietary cnvK puromycin-linker for stable genotype–phenotype coupling and supports screening of 10^13–10^14 molecular variants, and the PharmaLogical Library, a humanized synthetic VHH library designed from camelid structural data to minimize immunogenicity. These assets are packaged into a service called The Month, which delivers 50–100 antigen-binding clones with KD, Tm, and Tagg profiling data within approximately 30 business days.

EME monetizes primarily through fee-for-service contract research and joint research agreements with pharmaceutical companies and biotech firms, supplemented by technology and antibody licensing arrangements and reagent sales of the cnvK linker. Customers are predominantly Japanese pharmaceutical and biotech enterprises, including Kao Corporation, ONO Pharmaceutical, Kyowa Kirin, JCR Pharmaceuticals, AprilBio, and ASKA Pharmaceutical, with academic collaborations including Kitasato University and Savid Therapeutics. Pricing is custom-quoted per project scope with multi-year contracts typical.

The company's go-to-market is sales-led and event-driven, anchored on participation in BioJapan, CPHI Japan, LINK-J Symposium, PEGS Boston, and Antibody Engineering & Therapeutics. Strategic positioning has expanded beyond infectious disease and cancer into obstetrics/gynecology and into adjacent modalities via a VHH-CAR-T program and an Intrabody Library for intracellular targets. The most recent strategic event is a June 2026 capital partnership with CDMO Sanyo Fine Co., Ltd., paired with a third-party share allocation from the Saitama Shibusawa MIX Innovation Creation Support Fund, signaling capacity and capital build ahead of the next phase of growth.

Name

Epsilon Molecular Engineering

Legal name

株式会社Epsilon Molecular Engineering

Website

https://epsilon-mol.co.jp

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Epsilon Molecular Engineering is a Japanese contract research organization operating a proprietary cDNA display-based VHH antibody discovery platform, offering the PharmaLogical Library, The Month screening service, and licensing to pharmaceutical and biotech customers in Japan and internationally.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Antibody Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

CAR-T & TCR-T Therapies (HLAAABAC), Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF)

Keywords

• VHH antibody discovery
• Contract research services
• CDNA display technology
• Biopharmaceutical drug discovery
• Antibody screening platform

Headquarters

HQ city

Saitama

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. VHH Antibody Discovery Services: Providing pharmaceutical companies with high-throughput VHH antibody screening and profiling services using the proprietary 'The Month' platform. Revenue generated through contract research agreements and service fees.
2. Technology Licensing: Licensing of VHH antibodies, PharmaLogical Library technology, and cDNA display methodologies to pharmaceutical and biotech companies for their internal drug discovery programs.
3. cnvK Linker Sales: Sale of proprietary cnvK linker reagents for cDNA display applications to research institutions and biotech companies.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Epsilon Molecular Engineering (EME) provides high-throughput VHH (Variable domain of heavy-chain antibody) antibody discovery services for pharmaceutical and biotech customers, combining a proprietary humanized synthetic VHH library (PharmaLogical® Library) with cDNA display in vitro screening technology. Its 'The Month' platform delivers 50–100 antigen-binding clones with KD, Tm, and aggregation data within approximately 30 business days, supporting drug discovery, in vitro diagnostics, and technology licensing. Additional offerings include the proprietary cnvK linker reagent and a specialized Intrabody Library for intracellular targeting applications.

Product overview

Epsilon Molecular Engineering (EME) offers an integrated VHH antibody discovery platform comprising three core offerings: PharmaLogical® Library (artificial humanized VHH library with 10^13-14 diversity), cDNA Display Technology (in vitro screening platform enabling 1000x larger library vs. phage display), and The Month (high-throughput screening service delivering 50-100 antigen-binding clones in ~30 business days). The platform supports drug discovery, diagnostic development, and licensing across therapeutics, diagnostics, and imaging applications. Supporting products include the proprietary cnvK linker for cDNA display and specialized Intrabody Library for intracellular targeting.

Differentiator

Problem solved

Functional benefit

Products and services

• VHH Antibody Discovery Service Contract research service for discovering VHH antibodies targeting specific antigens. Includes screening, profiling, and optimization of VHH candidates for pharmaceutical drug discovery, diagnostics, and research applications.
• The Month Screening Platform High-throughput VHH screening and profiling service combining PharmaLogical® Library with cDNA display technology. Enables isolation of 50-100 antigen-binding clones within approximately one month, delivering KD values, Tm (denaturation temperature), and Tagg (aggregation temperature) data.
• PharmaLogical® Library Licensing Licensing of the PharmaLogical® Library technology to pharmaceutical and biotech companies for use in their internal drug discovery programs.
• cDNA Display Technology Licensing Licensing of proprietary cDNA display methodologies, including the cnvK linker technology, to pharmaceutical and biotech companies for use in their own drug discovery platforms.
• cnvK Linker Reagent Proprietary puromycin-linker reagent sold to research institutions and biotech companies for cDNA display applications, enabling rapid and stable genotype-phenotype coupling through UV cross-linking.

Quantifiable outcome

• 30 business days to obtain functional, stable hit clones
• +2 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered major and minor.

• AprilBiomajorStrategic or Co-development Partner · 11 April 2025Joint development of next-generation VHH antibody therapeutics combining both companies' technologies.
• ONO PharmaceuticalmajorStrategic or Co-development Partner · 21 February 2024Collaboration agreement for creating novel VHH antibody drugs for unmet medical needs.
• Kao CorporationmajorStrategic or Co-development Partner · 28 July 2023Comprehensive collaboration agreement covering multiple infectious disease targets using PharmaLogical VHH antibodies.
• ASKA PharmaceuticalminorStrategic or Co-development Partner · 7 February 2023Collaboration to address unmet medical needs in obstetrics and gynecology using novel PharmaLogical VHH antibodies.
• Kyowa KirinmajorStrategic or Co-development Partner · 26 October 2021Research agreement focused on VHH antibody development for therapeutic applications.
• JCR PharmaceuticalsmajorStrategic or Co-development Partner · 28 September 2021Collaboration on drug discovery and development using VHH antibodies for various therapeutic indications.
• Kao CorporationmajorStrategic or Co-development Partner · 23 December 2020Comprehensive collaboration for multiple infectious diseases utilizing PharmaLogical VHH antibodies. Kao contributed protein production expertise to COVID-19 VHH development.
• Savid TherapeuticsminorStrategic or Co-development Partner · 1 September 2020Joint research on VHH antibodies for cancer photodynamic therapy. EME provides VHH antibodies while Savid contributes their Cupid-Psyche platform technology.

Scale indicators4 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Argenx: Global leader in VHH/nanobody therapeutics with multiple approved products (efgartigimod). Direct competitor in VHH discovery and development; business model aligns on using camelid-derived VHHs for therapeutic applications, though Argenx is at commercial rather than services scale.
• Crescendo Biologics: Clinical-stage VHH-based T-cell engager company developing Humabody therapeutics. Comparable as a VHH-focused platform building modular, humanized VH domain therapeutics for oncology and immunology.
• Elasmogen: Developer of soloMER (single-domain VHH-like) biologics for inflammatory disease and oncology. Direct peer in the VHH/nanobody therapeutics space with a comparable humanized single-domain platform.
• AdAlta: Clinical-stage Australian biotech with an i-body (single-domain VHH-like) discovery platform. Comparable as a smaller, platform-based VHH/nanobody company serving therapeutic and diagnostic applications.
• Isogenica: UK-based VHH and single-domain antibody discovery company using in vitro display technologies. Direct peer as a smaller, service-and-licensing-oriented VHH discovery firm with similar business model.

Emerging players

• Harbour BioMed: Asia-based biotech (notably operating in Greater China and the Netherlands) with VHH-based programs including HBM7008. Comparable as a VHH therapeutic developer with regional Asia exposure, though at a more advanced clinical stage than EME.
• Gammadelta Therapeutics: UK-based biotech developing γδ T-cell therapies with VHH antibody components. Comparable as an emerging player applying VHH technology to cell therapy, intersecting with EME's VHH-CAR-T development line.

Broad incumbents

• AbCellera Biologics: Large publicly-traded antibody discovery platform operating single-cell screening at massive scale. Comparable as a high-throughput antibody discovery and licensing partner serving pharma, but broader (mAb + VHH) and at much greater scale.
• Twist Bioscience: Synthetic DNA and antibody library provider offering phage-display libraries and antibody optimization services. Comparable as a synthetic-library-enabled antibody discovery supplier, though serving a broader customer base than EME's VHH focus.
• AnaptysBio: Clinical-stage immunology biotech with internal antibody discovery capabilities and pharma partnerships. Comparable as a therapeutic antibody discovery firm with partnership-driven business model, though broader and clinical-stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/epsilon-molecular-engineering-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epsilon Molecular Engineering